Last updated on July 2019

Paclitaxel Trastuzumab and Pertuzumab With or Without Atezolizumab in Treating Patients With Metastatic Breast Cancer


Brief description of study

This randomized phase III trial studies how well paclitaxel, trastuzumab, and pertuzumab with or without atezolizumab works in treating patients with breast cancer that has spread to other parts of the body. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with trastuzumab, pertuzumab, and atezolizumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether giving paclitaxel, trastuzumab, and pertuzumab with or without atezolizumab may kill more tumor cells.

Detailed Study Description

PRIMARY OBJECTIVES:

I. To determine whether the addition of atezolizumab to a regimen of paclitaxel, pertuzumab, and trastuzumab will improve the progression-free survival (PFS), as assessed by investigator using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria, relative to a regimen of paclitaxel, pertuzumab, trastuzumab, and placebo in patients with newly documented HER2-positive measurable metastatic breast cancer.

SECONDARY OBJECTIVES:

I. To determine whether the addition of atezolizumab to a regimen of paclitaxel, pertuzumab, and trastuzumab will improve the overall survival (OS) relative to a regimen of paclitaxel, pertuzumab, trastuzumab, and placebo.

II. To determine whether the addition of atezolizumab to a regimen of paclitaxel, pertuzumab, and trastuzumab will improve the overall objective response (OR), assessed by investigator using RECIST 1.1 criteria, relative to a regimen of paclitaxel, pertuzumab, trastuzumab, and placebo.

III. To determine whether the addition of atezolizumab to a regimen of paclitaxel, pertuzumab, and trastuzumab will improve PFS, OR, and/or duration of objective response assessed by retrospective blinded central review using RECIST 1.1 criteria, relative to a regimen of paclitaxel, pertuzumab, trastuzumab, and placebo.

IV. To determine whether the addition of atezolizumab to a regimen of paclitaxel, pertuzumab, and trastuzumab will decrease the incidence of subsequent brain metastases in patients without known brain metastases at study entry relative to a regimen of paclitaxel, pertuzumab, trastuzumab, and placebo.

V. To determine whether the addition of atezolizumab to a regimen of paclitaxel, pertuzumab, and trastuzumab will contribute to increased patient-reported fatigue in comparison to a regimen of paclitaxel, pertuzumab, trastuzumab, and placebo.

VI. To determine the utility of PD-L1 immunohistochemistry (IHC) staining as a predictive and prognostic biomarker associated with clinical response, as assessed by investigator using RECIST 1.1 criteria, to atezolizumab in combination with paclitaxel, trastuzumab, and pertuzumab.

VII. To determine the immune-related toxicity profile of the two treatment regimens.

VIII. To determine the cardiac safety profile of the two treatment regimens.

EXPLORATORY OBJECTIVES:

I. To determine whether the addition of atezolizumab to a regimen of paclitaxel, pertuzumab, and trastuzumab will improve the progression-free survival and overall objective response, assessed by investigator using immune-modified RECIST (iRECIST) criteria, relative to a regimen of paclitaxel, pertuzumab, trastuzumab, and placebo.

II. To identify potential biomarkers that can predict benefit from the addition of atezolizumab in patients with newly documented HER2-positive measurable metastatic breast cancer treated with a regimen of paclitaxel, pertuzumab, and trastuzumab, and placebo.

III. To explore the toxicity profile of the two treatment regimens using patient-reported symptomatic adverse events in addition to standard adverse event reports.

IV. To determine the feasibility and added value of frequent assessment of toxicity using Patient Reported Outcomes (PRO)-Common Terminology Criteria for Adverse Events (CTCAE) with electronic(e)PRO reporting.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive pertuzumab intravenously (IV) over 30-60 minutes on days 1 and 22, trastuzumab IV over 30-90 minutes on days 1 and 22, paclitaxel IV over 60 minutes on days 1, 8, 15, 22, 29, and 36, and atezolizumab IV over 60 minutes on days 1 and 22. Cycles for pertuzumab, trastuzumab and atezolizumab repeat every 6 weeks and treatment with paclitaxel repeats every 6 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients may receive additional 3 cycles of paclitaxel in the absence of progression at the investigator's discretion.

ARM II: Patients receive pertuzumab, trastuzumab, and paclitaxel as in Arm I. Patients also receive placebo IV over 60 minutes on days 1 and 22. Cycles for pertuzumab, trastuzumab, and placebo repeat every 6 weeks and treatment with paclitaxel repeats every 6 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients may receive additional 3 cycles of paclitaxel in the absence of progression at the investigator's discretion.

After completion of study treatment, patients are followed up every 3 months for 3 years and then every 6 months for 4 years.

Clinical Study Identifier: NCT03199885

Find a site near you

Start Over

Mary Bird Perkins Cancer Center

Baton Rouge, LA United States
  Connect »

Woman's Hospital

Baton Rouge, LA United States
  Connect »

MetroHealth Medical Center

Cleveland, OH United States
  Connect »

Presbyterian Kaseman Hospital

Albuquerque, NM United States
  Connect »

Ingalls Memorial Hospital

Harvey, IL United States
  Connect »

Illinois CancerCare-Bloomington

Bloomington, IL United States
  Connect »

Illinois CancerCare-Carthage

Carthage, IL United States
  Connect »

Illinois CancerCare-Galesburg

Galesburg, IL United States
  Connect »

Illinois CancerCare-Princeton

Princeton, IL United States
  Connect »

Adena Regional Medical Center

Chillicothe, OH United States
  Connect »

Grant Medical Center

Columbus, OH United States
  Connect »

Doctors Hospital

Columbus, OH United States
  Connect »

OhioHealth Mansfield Hospital

Mansfield, OH United States
  Connect »

Marietta Memorial Hospital

Marietta, OH United States
  Connect »

Licking Memorial Hospital

Newark, OH United States
  Connect »

Southern Ohio Medical Center

Portsmouth, OH United States
  Connect »

Crossroads Cancer Center

Effingham, IL United States
  Connect »

Saint Francis Medical Center

Cape Girardeau, MO United States
  Connect »

Saint Joseph Mercy Hospital

Ann Arbor, MI United States
  Connect »

Saint Joseph Mercy Brighton

Brighton, MI United States
  Connect »

Saint Joseph Mercy Canton

Canton, MI United States
  Connect »

Saint Joseph Mercy Chelsea

Chelsea, MI United States
  Connect »

Hope Cancer Clinic

Livonia, MI United States
  Connect »

Saint Mary Mercy Hospital

Livonia, MI United States
  Connect »

Beebe Health Campus

Rehoboth Beach, DE United States
  Connect »

Park Nicollet Clinic - Saint Louis Park

Saint Louis Park, MN United States
  Connect »

Northside Hospital

Atlanta, GA United States
  Connect »

Caro Cancer Center

Caro, MI United States
  Connect »

Ascension Saint Joseph Hospital

Tawas City, MI United States
  Connect »

Capital Region Southwest Campus

Jefferson City, MO United States
  Connect »

Bozeman Deaconess Hospital

Bozeman, MT United States
  Connect »

Shenandoah Oncology PC

Winchester, VA United States
  Connect »

Virginia Cancer Institute

Richmond, VA United States
  Connect »

Katmai Oncology Group

Anchorage, AK United States
  Connect »

Geauga Hospital

Chardon, OH United States
  Connect »

UHHS-Westlake Medical Center

Westlake, OH United States
  Connect »

Randolph Hospital

Asheboro, NC United States
  Connect »

Cone Health Cancer Center

Greensboro, NC United States
  Connect »

Bryn Mawr Hospital

Bryn Mawr, PA United States
  Connect »

Riddle Memorial Hospital

Media, PA United States
  Connect »

Paoli Memorial Hospital

Paoli, PA United States
  Connect »

Lankenau Medical Center

Wynnewood, PA United States
  Connect »

Vidant Oncology-Kenansville

Kenansville, NC United States
  Connect »

Vidant Oncology-Kinston

Kinston, NC United States
  Connect »

Vidant Oncology-Richlands

Richlands, NC United States
  Connect »

Avera Cancer Institute

Sioux Falls, SD United States
  Connect »

McFarland Clinic PC-Jefferson

Jefferson, IA United States
  Connect »

McFarland Clinic PC-Marshalltown

Marshalltown, IA United States
  Connect »

Memorial Hospital of South Bend

South Bend, IN United States
  Connect »

Iowa Methodist Medical Center

Des Moines, IA United States
  Connect »

Broadlawns Medical Center

Des Moines, IA United States
  Connect »

Trinity Regional Medical Center

Fort Dodge, IA United States
  Connect »

Missouri Baptist Medical Center

Saint Louis, MO United States
  Connect »

Aspirus UW Cancer Center

Wisconsin Rapids, WI United States
  Connect »

Springfield Clinic

Springfield, IL United States
  Connect »

Mercy Hospital

Cedar Rapids, IA United States
  Connect »

Reading Hospital

West Reading, PA United States
  Connect »

UPMC Susquehanna

Williamsport, PA United States
  Connect »

Lexington Medical Center

West Columbia, SC United States
  Connect »

Hawaii Oncology Inc-POB I

Honolulu, HI United States
  Connect »

Hawaii Oncology Inc-Kuakini

Honolulu, HI United States
  Connect »

University of Rochester

Rochester, NY United States
  Connect »

Nash General Hospital

Rocky Mount, NC United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.